Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients

Table 5

More than twofold declined or elevated lipid elements of NSCLC patients with bad response and good response in pre-RT, RT, or post-RT groups ( or less).

Bad/good response pre-RT			Bad/good response RT			Bad/good response post-RT
Elements	Fold change	value	Elements	Fold change	value	Elements	Fold change	value
PG (18 : 0/14 : 0)	0.256	0.004	PA (16 : 0/18 : 1)	0.341	0.009	PI (14 : 0/22 : 4)	2.003	0.041
PG (18 : 1/18 : 3)	0.333	0.022	PG (18 : 2/20 : 3)	0.490	0.045	LPA (18 : 2)	2.029	0.024
PG (18 : 0/20 : 1)	0.423	0.006	PA (18 : 0/18 : 0)	2.496	0.002	FFA (16 : 2)	2.053	0.013
27 OH cholesterol	2.084	0.043	PI (20 : 0/18 : 3)	2.525	0.037	PS (20 : 0/18 : 1)	2.072	<0.001
PA (14 : 0/20 : 4)	2.138	0.023				MAG 16 : 1	2.229	0.041
PA (14 : 0/20 : 3)	2.141	0.035				PA (18 : 2/22 : 6)	2.243	0.006
PA (18 : 2/22 : 4)	2.174	0.027				MAG 18 : 1	2.323	0.007
PS (14 : 0/22 : 4)	2.290	0.015				PI (16 : 0/18 : 2)	2.351	0.011
PI (20 : 0/22 : 5)	2.319	0.045				FFA (20 : 0)	2.355	0.010
PI (14 : 0/22 : 4)	2.480	0.025				FFA (24 : 0)	2.490	0.024
						LPS (22 : 4)	2.572	0.048
						PA (14 : 0/22 : 4)	2.921	0.001
						PA (14 : 0/20 : 5)	3.199	0.043
						PG (20 : 0/22 : 5)	3.799	0.001
						MAG 22 : 3	5.027	0.034

NSCLC: non-small-cell lung cancer; pre-RT: preradiotherapy; RT: radiotherapy; post-RT: postradiotherapy.